A number of other analysts have also issued reports on AZN. Piper Jaffray Companies reiterated a buy rating on shares of Astrazeneca PLC in a research note on Wednesday, August 9th. BidaskClub lowered shares of Astrazeneca PLC from a sell rating to a strong sell rating in a research note on Friday, August 4th. Cowen and Company reiterated a hold rating and set a $37.00 price objective on shares of Astrazeneca PLC in a research note on Tuesday, October 17th. Credit Suisse Group upgraded shares of Astrazeneca PLC from a neutral rating to an outperform rating in a research note on Monday, October 16th. Finally, Investec raised shares of Astrazeneca PLC from a hold rating to a buy rating in a research report on Wednesday, August 9th. Four investment analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have issued a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of $34.20.
Astrazeneca PLC (NYSE:AZN) opened at $32.91 on Tuesday. Astrazeneca PLC has a 1-year low of $25.55 and a 1-year high of $35.60. The company has a debt-to-equity ratio of 1.09, a current ratio of 0.91 and a quick ratio of 0.73. The company has a market cap of $83,831.08, a P/E ratio of 7.90, a P/E/G ratio of 2.77 and a beta of 0.75.
Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings results on Thursday, November 9th. The company reported $1.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.57 by $0.55. The firm had revenue of $6.23 billion for the quarter, compared to analyst estimates of $6 billion. Astrazeneca PLC had a net margin of 15.90% and a return on equity of 33.93%. Astrazeneca PLC’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.32 earnings per share. equities analysts expect that Astrazeneca PLC will post 1.93 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Meeder Asset Management Inc. bought a new stake in shares of Astrazeneca PLC during the second quarter valued at about $105,000. WFG Advisors LP raised its stake in shares of Astrazeneca PLC by 36.0% during the second quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock valued at $127,000 after purchasing an additional 984 shares in the last quarter. Bronfman E.L. Rothschild L.P. raised its position in Astrazeneca PLC by 71.2% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock worth $145,000 after acquiring an additional 1,769 shares in the last quarter. Westport Asset Management Inc. bought a new stake in Astrazeneca PLC in the second quarter worth about $170,000. Finally, First Interstate Bank raised its position in Astrazeneca PLC by 10.3% in the second quarter. First Interstate Bank now owns 5,127 shares of the company’s stock worth $175,000 after acquiring an additional 480 shares in the last quarter. Institutional investors and hedge funds own 14.17% of the company’s stock.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with our FREE daily email newsletter.